Residual risk stratification of Taiwanese breast cancers following curative therapies with the extended concurrent genes signature.

Archived FFPE samples could be successfully assayed by the NanoString nCounter. The purposed signature was prognostic stratifying breast cancer patients into groups with distinct survival patterns, and clinical applicability of the residual risk model was proved.